In human studies, Nrf2 suppression has been linked to cataract formation in lenses collected from diabetic and older patients, with the upregulation of Keap1 (an Nrf2 suppressor) found in these individuals
Tirzepatide India: Lilly and Cipla Expand Access to Advanced Diabetes and Obesity Care India may soon see wider access to Tirzepatide, one of the most potent therapies approved for use in people with type 2 diabetes and chronic weight management, as Eli Lilly and Company India recently signed an agreement with Cipla Limited, allowing the pharmaceutical company Cipla to distribute and promote the drug under a second brand name Yurpeak throughout India
It is used in 10-20% concentrations and easily treats inflammatory hyperpigmentation
While probiotics such as Bifidobacterium and Lactobacillus have shown potential in restoring gut microbial balance and modulating immune responses, their clinical application remains largely isolated, often lacking synergistic prebiotic supplementation (Ouyang et al., 2024)
Still, changes in DNA have been identified that could be meaningful in the identification and design of the next therapeutic strategies
Dosing Clarification: Why Dose Escalation Doesn't Require a Second Drug GLP-1 treatment begins at a low dose (0.25 mg semaglutide weekly) and increases incrementally every 4 weeks based on tolerance and response
